Significant improvement of a nevus spilus-type congenital melanocytic nevus with oral selumetinib.
MEK inhibitor
NRAS
kaposiform lymphangiomatosis
nevus spilus
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
17 Jun 2024
17 Jun 2024
Historique:
received:
16
02
2024
accepted:
12
05
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
Giant congenital melanocytic nevi (GCMN) can be cosmetically significant and can lead to melanoma. There is no standard pharmacologic treatment for GCMN. We present the case of an 8-year-old female with kaposiform lymphangiomatosis caused by an NRAS mutation whose nevus spilus-type GCMN improved on oral selumetinib.
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Pediatric Dermatology published by Wiley Periodicals LLC.
Références
Kinsler VA, Krengel S, Riviere JB, et al. Next‐generation sequencing of nevus spilus‐type congenital melanocytic nevus: exquisite genotype‐phenotype correlation in mosaic RASopathies. J Invest Dermatol. 2014;134(10):2658‐2660.
Krengel S, Widmer DS, Kerl K, Levesque MP, Schiestl C, Weibel L. Naevus spilus‐type congenital melanocytic naevus associated with a novel NRAS codon 61 mutation. Brit J Dermatol. 2016;174(3):642‐644.
Mir A, Agim NG, Kane AA, Josephs SC, Park JY, Ludwig K. Giant congenital melanocytic nevus treated with trametinib. Pediatrics. 2019;143(3):e20182469.
Molho‐Pessach V, Hartshtark S, Merims S, et al. Giant congenital melanocytic naevus with a novel CUX1‐BRAF fusion mutation treated with trametinib. Br J Dermatol. 2022;187(6):1052‐1054.
Martin SB, Polubothu S, Bruzos AL, et al. Mosaic BRAF fusions are a recurrent cause of congenital melanocytic nevi targetable by MAPK pathway inhibition. J Invest Dermatol. 2024;144(3):593‐600.e7.